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Abstract. Leishmaniasis comprises a group of diseases caused by 
protozoa of the genus Leishmania and has two basic clinical forms, 
visceral Leishmaniasis and cutaneous Leishmaniasis. The clinical 
features of Leishmaniasis depend on the species of Leishmania, the 
interaction between host and parasite and the immune response. 
      This work focuses on cutaneous leishmaniosis because 
although it is not a deadly disease it results in significant scars and 
facial disfigurements, thus being clinically important. Furthermore, 
the first-line treatment consists of intravenous or intramuscular 
administration of intralesional pentavalent antimonials, which are 
highly toxic, making hospitalization of patients compulsory during 
treatment, with the associated financial costs. Herein, we review 
studies on drugs and treatments with fewer side effects and easier 
routes of administration such as topical administration. Recent 
research shows that the topical route of administration holds 
promise for the future treatment of cutaneous leishmaniosis.  
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Introduction 
   
1.1. Overview of Leishmaniasis     
 
 Leishmaniasis comprises a group of diseases caused by protozoan 
parasites of the genus Leishmania. There are two main clinical forms, 
visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). It is 
transmitted by vectors of the genus Phlebotomus and Lutzomyia in Europe 
and America respectively, and a large number of vertebrates act as reservoirs. 
It is considered a zoonosis in most cases, and can affect around 100 species 
of animals including humans [1]. 
 The World Health Organization (WHO) has reported a wide distribution 
of leishmaniasis, extending from South America, Africa and Asia to Europe. 
The disease is endemic in 88 countries, 72 of which are developing countries 
(Fig. 1 and 2). According to the WHO, as many as 12 million people are 
believed to be currently infected, with about 1–2 million estimated new cases 
occurring every year of which 500,000 are VL (90% in India and Sudan) and 
1,000,000 are CL (90% Afghanistan, Saudi Arabia, Algeria, Brazil, Iraq, 
Iran, Syria and Sudan). Furthermore, a total of 350 million people live in risk 
areas. 
 
 
 
Figure 1. Areas of the world affected by leishmaniasis. The visceral form is shown in 
green and the cutaneous and mucocutaneous form in red (WHO). 
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Figure 2. Global distribution of cutaneous Leishmaniasis (WHO). 
 
Aetiological agent 
 
 The genus Leishmania contains a number of species. Its taxonomic status 
is as follows (Lainson and Shaw, 1987): 
 
Phylum: Sarcomastigophora (Honigberg & Balamuth, 1963). 
Subphylum: Mastigophora (Diesing, 1866). 
Class: Zoomastigophorea (Calkins, 1909). 
Order: Kinetoplastida (Vickerman, 1976). 
Suborder: Trypanosomatina (Kent, 1880). 
Family: Trypanosomatidae (Gobben, 1905). 
Genus: Leishmania (Ross, 1903). 
 
 About 29 species of Leishmania have been described, of which 21 have 
been isolated from humans. These are responsible for producing the different 
clinical forms of the disease with a wide range of clinical symptoms. The 
species are grouped according to their geographical distribution in the Old 
and the New World, and their main clinical form: visceral, cutaneous or 
mucocutaneous. Cutaneous leishmaniasis is the most common form. Visceral 
leishmaniasis is the most severe form, in which vital organs of the body are 
affected. The same species can be found in both geographical areas, and can 
be responsible for more than one clinical form (Table 1). 
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Table 1. Classification of different species of Leishmania in human species, 
geographical distribution and clinical form (WHO, 2010). 
 
 Leishmania found in humans 
 
Subgenus L.(Leishmania) L.(Leishmania) L. (Viannia) L. (Viannia) 
Old World L. donovani L. major   
 L. infantum L. tropica   
  L. killicki
a   
  L. aethiopica   
  L. infantum   
New World L. infantum L. infantum L. braziliensis L. braziliensis 
  L. mexicana L. guyanensis L. panamensis 
  L. pifanol
a L. panamensis  
  L. gamhami
a L. shawi  
  L. amazonensis L. naiffi  
   L. lainsoni  
   L. lindenbergi  
   L. peruviana  
   L. colombiensis
b  
Principal 
tropism 
Viscerotropic Dermotropic Dermotropic Mucotropic 
 
aSpecies status is under discussion 
bTaxonomic position is under discussion 
 
1.2. Morphology and life cycle 
 
 The life cycle of Leishmania involves transfer between a vertebrate host 
and an invertebrate host, with two main morphological forms: 
 
- Amastigote form: it is reproduced within macrophages and cells of the 
mononuclear phagocyte system of vertebrate host. It is oval,                           
without a flagellum, and is therefore immobile. It measures about 2.5 to 7 
μm in diameter. The cytoplasm contains a nucleus and kinetonuclei                  
(Fig. 3). 
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Figure 3. Amastigote form (WHO).            Figure 4. Promastigote form (WHO). 
 
- Promastigote form: the parasite is a motile form with an anterior 
flagellum that develops in the sandfly, the insect vector. It is larger than the 
amastigote form. It has a central oval nucleus and prenuclear kinetonuclei 
(Fig. 4). 
 The cycle begins when the vector of female sand flies (invertebrate host) 
ingests blood of the vertebrate host and inoculates infective promastigotes, 
also called metacyclics. These promastigotes are phagocytized by 
macrophages in the skin, mucosal membranes and viscera. Within the 
cytoplasm of macrophages, the promastigotes transform into amastigotes. 
The amastigotes multiply until the cell explodes. Free parasites invade other 
macrophages or spread directly through the skin or the systemic circulation. 
Macrophages loaded with amastigotes can be re-ingested by the vector at a 
recent sting and then transform into promastigotes in the digestive tract. The 
promastigote form develops into a metacyclic infectious form over 
approximately 10 days. 
 
1.3. Clinical manifestations of Leishmaniasis 
 
 The clinical manifestations of leishmaniasis are varied and depend on the 
species of Leishmania, the interaction between host and parasite and the host 
immune response [2-4]. This polymorphism is grouped into three different 
clinical forms: 
 
Cutaneous Leishmaniasis  
 
 There is a wide variety of clinical presentations. A ‘classical’ lesion starts 
as a papule or nodule at the site of inoculation; it grows slowly, taking at least 
1 week to reach its final size. Generally it is a single lesion located on the 
face, arms or legs. A crust develops centrally, which may fall away, exposing 
Alba Pujol & Cristina Riera  186 
an ulcer up to 5 cm in diameter with a raised edge and variable surrounding 
induration, which heals gradually over months or years, leaving a depressed 
scar with altered pigmentation. Satellite nodules at the edge of the lesion are 
common. Occasionally, it may be complicated with bacterial superinfection 
or regional lymphadenopathy [5] (Fig. 5A). 
 
Mucocutaneous Leishmaniasis 
 
 This clinical form occurs in just a few species of the New World. Studies 
in Brazil have shown that mucocutaneous leishmaniasis can present from 
several months to 20 or more years after a cutaneous lesion. Nasal lesions are 
always present, with nodules and infiltration of the anterior cartilaginous 
septum, leading to obstruction of the nostril and, later, perforation of the 
septum with collapse and broadening of the nose. In one third of patients, 
other sites are involved, in the following descending order of frequency: the 
pharynx, palate, larynx, trachea and upper lip. Mucocutaneous leishmaniasis 
almost never heals spontaneously. Secondary bacterial infections are 
frequent, intercurrent pneumonia being the commonest cause of death                 
(Fig. 5B). 
 
Visceral Leishmaniasis or Kala azar 
 
 This is the most severe form of leishmaniasis. Clinically it is 
characterized by the appearance of fever, vomiting, shivering, diarrhoea, 
weight loss and anaemia. The common clinical signs are non-tender 
splenomegaly, with or without hepatomegaly, wasting and pallor of mucous 
membranes. In more advanced cases clotting disorders occur. Without 
treatment, it can lead to death (Fig. 5C). 
 
 
 
Figure 5. Cutaneous Leishmaniasis (A), mucocutaneous leishmaniasis (B), visceral 
leishmaniasis [6] (C). 
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1.4. Cutaneous Leishmaniasis: Its problematic healthcare 
 
 Cutaneous leishmaniasis is not deadly, and some forms may heal 
spontaneously with time, but others may leave significant scarring, resulting 
in disfigurements to the face that are a barrier to finding work or marriage, 
especially for women. This in turn leads to social and economic 
consequences and increased poverty [7]. 
 Another important point to remember from health and epidemiological 
points of view is that patients with lesions act as reservoirs of infection, and 
thus without treatment the potential for transmission increases. Unfortunately 
the high cost of treatment means that in many cases it does not reach poor 
people [7]. 
 According to the WHO (2010), the main problem with cutaneous 
leishmaniasis relates to access to treatment, because the cost of 
hospitalization is added to the drug and may not be affordable in developing 
countries. For this reason and because leishmaniasis is one of a group of 
neglected diseases, the Drugs For Neglected Disease Initiative (DNDi) has 
highlighted the urgent need for affordable and effective drugs with short 
treatment schedules and uncomplicated  management (such as topical 
administration) that do not require complex health infrastructures. 
 The first-line treatment of cutaneous leishmaniasis is based on 
pentavalent antimonial drugs that can be administered in intravenous or 
intramuscular form or by intralesional injection, depending on the severity of 
the injury and the species responsible. These drugs are highly toxic, so it is 
necessary to hospitalize patients, which is very expensive in developing 
countries. Drugs with fewer toxic effects, such as liposomal amphotericin B 
(Ambisome®), can be administered in cases of complicated cutaneous and 
mucocutaneous leishmaniasis, but these are costly and are not widely 
available in countries with a high poverty index. 
 Herein we review existing conventional treatments currently available for 
cutaneous leishmaniasis and describe the different drugs and therapies 
currently used, as well as the different treatment regimens specific to the Old 
World and the New World. Also, we report on new treatments for cutaneous 
leishmaniasis that are currently being tested and studied: studies of new 
drugs, formulations, and drug combinations. 
 
2. Conventional treatments for cutaneous Leishmaniasis 
 
 There are currently several therapies for the treatment of leishmaniasis. 
The most commonly used compounds are pentavalent antimonials, and these 
are considered the drugs of first choice in the treatment and control of 
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leishmaniasis. Alternatives include the liposomal amphotericin B, the 
pentamidine paramomycin, drugs derived from imidazole, and an orally 
administered drug, miltefosine [8]. 
 Treatment of cutaneous leishmaniasis involves a combination of topical, 
systemic and non-pharmacological approaches. The therapeutic decision 
depends on the infecting species and geographic region. 
 
2.1. Pentavalent antimonials 
 
 Two pentavalent antimonials are available: sodium stibogluconate (SSG, 
Pentostam
®
) (Fig. 6A) and meglumine antimoniate (AMG, Glucantime
®
) 
(Fig. 6B). These have been used since the 1940s and are the first-line 
therapeutic agents for cutaneous leishmaniasis. 
 They cannot be administered orally. The recommended dose is               
20 mg/kg/day sodium stibogluconate intramuscularly or intravenously for     
20 days or 60 mg/kg/day of meglumine antimoniate. The principal problems 
encountered are their cost, toxicity and emergence of resistance. Intralesional 
administration at a dose of 0.5 to 5 mL injected at the base of the lesion is 
also an option [9]. 
 
      
 
Figure 6. A. Sodium stibogluconate (Pentostam®). B. Meglumine  antimoniate             
(Glucantime®). 
 
2.2. Amphotericin B 
 
 This drug has low antifungal spectrum activity and is derived from 
Streptomyces nodosus. It shows high leishmanicidal activity by joining the 
parasite lipids. It is a second-line drug (Fig. 7). 
 A test dose of 1 mg, given by infusion, is recommended, followed by a 
full dose 4–6 h later. Infusion reactions are common. Nephrotoxicity is also 
common. Treatment should always be given in hospital to allow continuous 
monitoring of patients [9]. 
B A 
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Figure 7. Amphotericin  B. 
 
2.3. Pentamidine 
  
 This drug is an antiprotozoal compound that is considered a second-line 
drug with significant toxic effects (damage to the pancreas, kidney and bone 
marrow). The drug is given intramuscularly or, preferably, by intravenous 
infusion (Fig. 8). 
 
 
 
Figure 8. Pentamidine. 
 
2.4. Paromomycin 
 
 Paramomycin (aminosidine) is an aminoglycoside antibiotic, first 
isolated from Streptomyces krestomuceticus in the 1950s. It is usually 
administered intramuscularly. Its mechanism of action is inhibition of 
mitochondrial activity of Leishmania. It acts synergistically with antimonials 
and is often used in combination or as the therapy of second choice (Fig. 9). 
 
 
 
Figure 9. Paromomycin. 
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2.5. Medicines derived from imidazole 
 
– Ketoconazole: This is an antifungal drug that inhibits the synthesis of 
ergosterol in the membrane of the parasite. It has been proven effective in the 
treatment of cutaneous leishmaniasis (Berman, 1997) (Fig. 10). 
 
 
 
Figure 10. Ketoconazole. 
 
– Itraconazole: This is another antifungal drug with a similar effect to 
ketoconazole (Davidson, 1998), but improved pharmacokinetics (Fig. 11). 
 
 
 
Figure 11. Itraconazole. 
 
2.6. Miltefosine 
 
 This is an alkyl phospholipid (hexadecylphosphocholine) that was 
originally developed as an oral anticancer drug but was shown to have 
antileishmanial activity. It was the first oral agent effective against 
leishmaniasis and should only be administered once a day. Unlike other 
antileishmanial drugs, its mechanism of action involves disrupting cellular 
signaling pathways and the synthesis of cell membranes of the parasite 
through different mechanisms. Unfortunately the development of resistance is 
common [10, 11] (Fig. 12). 
 
 
 
Figure 12. Miltefosine. 
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3. Treatment of cutaneous Leishmaniasis in the Old and the 
New World 
 
 The choice of treatment is based mainly on the risk-benefit ratio for each 
patient, with different therapeutic interventions in the Old and the New 
World [8]. 
 
3.1. Cutaneous Leishmaniasis in the Old World 
 
 Old World cutaneous leishmaniasis is caused by five species of 
Leishmania: L. infantum, L. tropica, L. major, L. aethiopica and                         
L. donovani. These are mainly species of the Mediterranean coast, the Middle 
East and Africa. 
 Cutaneous lesions caused by L. infantum are seen especially in the 
Mediterranean basin. L. infantum is the most frequent cause of cutaneous 
leishmaniasis in southern Europe. The lesions are usually single nodules, 
with little inflammation but triggering an ulcer. The lesions heal 
spontaneously within about 1 year and seem to confer immunity [8]. 
 L. tropica, which causes anthroponotic or urban anthroponotic cutaneous 
leishmaniasis, is distributed mainly in Morocco, Saudi Arabia and West Asia. 
This leishmaniasis is characterized by the presence of multiple painless and 
dry ulcers of the skin. These generally heal spontaneously within a year, 
often leading to disfiguring scars [1].  
 Cutaneous leishmaniasis caused by L. major (previously known as 
zoonotic or rural zoonotic cutaneous leishmaniasis) is a rural zoonosis typical 
of North Africa, West Asia and Asia Minor. Like other forms of cutaneous 
leishmaniasis it is characterized by painless lesions and often severe 
inflammation and ulceration. These lesions heal after 2–8 months. Multiple 
lesions may occur, especially in nonimmune immigrants; these are slow to 
heal and can leave large disfiguring or disabling scars [1]. 
 Finally, cutaneous leishmaniasis, caused by L. aethiopica (Ethiopia, 
Kenya and Sudan), results mainly in localized cutaneous nodular lesions. A 
less frequent complication is mucocutaneous lesions of the oropharynx, 
causing a distortion of the nostrils of the nose and lips. Most lesions develop 
slowly and can spread locally. Ulceration is late or absent. Spontaneous 
healing usually occurs within 2–5 years. 
 
Established criteria for topical treatment 
  
 According to WHO guidelines, local treatment of the lesion is indicated 
in patients who meet the following requirements [8]: 
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- Confirmed or strongly suspected infection with L. major. 
- Fewer than four lesions requiring immediate treatment. 
- Lesions < 5 cm in diameter. 
- No potentially disfiguring or disabling lesions (face, joints, toes, fingers). 
- No immunosuppression. 
- Possibility of follow-up. 
 
The options for topical treatment are (Table 2) [8]: 
 
Intralesional therapy with pentavalent antimonials: injected at a dose of 
0.5 to 5 mL at the base and margins of the lesion between 3 and 7 days. 
Infiltration can be performed daily, on alternate days or weekly until healing 
of the lesion. These injections are effective but repetitive administration may 
lead to resistance. 
 
Table 2. Recommendations for treatment and dosage of Old World cutaneous 
leishmaniasis  (WHO 2010). 
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Paromomycin ointments: either a formulation of 15% paromomycin plus 
12% methyl benzethonium chloride (CLMB) or a formulation of 0.5% 
gentamicin and 15% paramomycin in paraffin, twice daily for up to                     
20 days. 
 
Thermotherapy: it consists of one or two applications of localized heat at 50 °C 
for 30 seconds. One of the drawbacks of this therapy is the high cost of the 
device and also the second-degree burns that occur. Local anaesthesia is 
therefore necessary. 
 
Cryotherapy: cryotherapy with liquid nitrogen (−195 °C) applied once or 
twice a week for up to 6 weeks. The application of liquid nitrogen requires 
specific devices and expensive specialist medical equipment. Although it is 
highly effective it is less effective than intralesional therapy with pentavalent 
antimony. 
 
 Local therapy is an attractive option with little toxicity, but 
thermotherapy and especially intralesional treatment cause significant 
discomfort. 
 
3.2. Cutaneous Leishmaniasis in the New World 
 
 Cutaneous leishmaniasis of the New World refers to infection caused 
by species found in Mexico, Central America and South America. These 
species belong to both the Leishmania and the Vianna subgenera, as 
follows: L. (L.) mexicana, L. (L.) amazonensis L. (V.) brazilensis, L. (V.) 
panamensis, L. (V.) guyanensis and L. (V.) peruviana [1]. 
 The clinical manifestations are similar to cutaneous leishmaniasis in the 
Old World but are usually more aggressive and tend to become chronic. 
Lesions caused by L. mexicana generally have a benign evolution, whereas  
L. amazonensis causes a single or multiple lesions that are resistant to 
treatment and have a high tendency to evolve to diffuse lesions.  
 On the other hand, species of the subgenus Vianna tend to form 
mucocutaneous lesions. These are normally single or multiple lesions that 
heal routinely, in the case of L. brazilensis, or have a low cure                         
rate (L. panamensis, L. guyanensis). If the lesion is located near a 
lymphatic chain or if treatment is inadequate the mucocutaneous form can 
develop. 
 Finally, L. peruviana is the most benign species because healing is 
spontaneous and there is no tendency to cause the mucocutaneous form.  
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 Local therapy is considered inadequate for the treatment of cutaneous 
leishmaniasis in the New World when caused by L. brazilensis or                         
L. panamensis, due to the potential risk of spread to mucous membranes. 
Topical treatment is currently considered acceptable in specific cases of 
cutaneous leishmaniasis in the New World.  
 
 Experience with local therapy for cutaneous leishmaniasis in the New 
World is limited. The criteria for the use of local treatment are similar to 
those of the Old World. The proposed options are thermotherapy and 
paramomycin. One to three applications of localized heat (50 °C for 30 
seconds) proved to be 70% effective in studies in Colombia and Guatemala, 
3 months after treatment. On the other hand, 15% and 12% paramomycin 
ointment applied twice daily for 20 days was 70–90% effective against 
cutaneous leishmaniasis caused by L. mexicana, L. panamensis and                    
L. brazilensis in Ecuador and Guatemala.  
 
 The options for systemic treatment are (Table 3) [8]: 
 
Pentavalent antimonials: The cure rate is very high at around 77% and 
90% when pentavalent antimonials are administered at a dose of 20 
mg/kg/day for 20 days intravenously or intramuscularly respectively. They 
are most effective against cutaneous leishmaniasis caused by L. braziliensis 
and L. panamensis. 
 
Pentamidine: Administered at a dose of 3–4 mg/kg on alternate days for a 
total of three or four doses intramuscularly, and is as effective as 
pentavalent antimonials against cutaneous leishmaniasis caused by                    
L. panamensis or L. guayanensis. However, it is less effective than 
antimonials in the case of L. brazilensis. 
 
Miltefosine: Oral miltefosine at a dose of 2 mg/kg/day for 28 days is 
effective against cutaneous leishmaniasis caused by L. panamensis but not 
against L. brazilensis or L. mexicana, for which the cure rate is less than 
60%. The response of L. brazilensis cutaneous leishmaniasis  to miltefosine 
may vary depending on the area. 
 
Ketoconazole: At a dosage of 600 mg daily for 28 days this is highly 
effective (76–90%) against L. panamensis and L. mexicana in Guatemala 
and Panama. 
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Table 3. Recommendations for treatment and dosage of New World cutaneous 
leishmaniasis (WHO, 2010). 
 
 
 
4. New treatments for cutaneous Leishmaniasis  
 
4.1. New drugs 
 
 Many of the drugs mentioned in the previous section have led to 
resistance in many species of Leishmania and consequently their 
effectiveness has diminished in areas in which the parasite was previously 
susceptible to such treatment. For this reason, many research groups have 
focused on investigating new therapeutic alternatives against 
leishmaniasis. The following table provides a summary of various natural 
products that have been reported to have leishmanicidal properties [12] 
(Table 4): 
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Table 4. Sources of essential oils with leishmanicidal properties [12]. 
 
Family Species Leishmania species 
Lauraceae Ocotea duckei L. infantum and L. 
amazonensis 
Rutaceae Dictyoloma peruviana L. amazonensis and L. 
brazilensis 
Verbenaceae Lyppia alba L. infantum 
Zingiberaceae Curcuma longa Leishmania spp. 
Myristicaceae Myristica malabàrica L. donovani 
Pinaceae Cedrus atlantica Leishmania spp. 
 
 Moreover, the importance of metal compounds in antiparasitic 
development is well known. For example, in vitro and in vivo studies of                 
L. major and L. tropica showed greater susceptibility to zinc than pentavalent 
antimony [13]. 
 Finally, a recent study examined the antileishmania effectiveness of a 
drug called buparvacuona, a hydroxynaphthoquinone used for the treatment 
of theileriosis in cattle. Specifically, the efficacy and toxicity of different 
topical formulations of buparvacuona against L. major were tested in vivo in 
BALB/c mice. The results of this study were encouraging, as parasite load 
and lesion size were reduced, and therefore the introduction of a topical 
formulation of this type would be a significant advance for the treatment of 
simple cutaneous lesions [14]. 
 The search for new drugs with antileishmanial activity is essential for 
new treatment options for cutaneous leishmaniasis. Avoiding the use of 
parenteral antimony would greatly increase patient compliance and reduce 
treatment costs. 
 
4.2. New formulations 
 
 As mentioned above, the standard topical treatment used at present is 
intralesional therapy with pentavalent antimony. However, this requires 
multiple injections, which are painful and not tolerated by most patients. 
Furthermore, they are not always effective, have many adverse effects and 
can lead to the development of resistance. Alternative topical therapies 
mainly contain paramomycin e.g. a formulation called WR 279,396, a 
hydrophilic formulation of paramomycin 15% and gentamicin 0.5% that is 
currently in a Phase III trial in Tunisia [15]. 
 Other researchers studied the permeability of the skin and the 
leishmanicidal activity of a hydrophilic gel containing 10% paramomycin in 
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vivo in experimental mice infected with L. major and compared its activity 
with parenteral pentavalent antimony. The gel showed higher efficiency than 
the pentavalent antimony administered intravenously. The same formulation 
was tested on hamsters infected with L. brazilensis and showed similar 
efficacy to that of parenteral antimony [16]. 
 Other authors studied a new topical formulation containing amphotericin 
B and evaluated its leishmanicidal effectiveness in CBA mice as a model for 
human cutaneous leishmaniasis. For the first time, they showed that 
amphotericin B administered topically as a complex with phospholipids or 
with cholesterol sulphate in the presence of ethanol can penetrate the skin and 
act in a localized manner even at very low concentrations, which therefore 
makes it less toxic [17]. 
 Liposomes have been widely used as drug delivery systems to treat 
infections caused by bacteria, fungi, viruses and parasites. These are 
nanometric spherical vesicles containing one or more phospholipid bilayers 
[18]. Their molecular architecture can capture a wide variety of active agents, 
thus providing a means of transport to bring drugs to their sites of action at 
appropriate concentrations, in turn ensuring a safe and effective 
pharmacological response. Furthermore, they are biodegradable, non-toxic 
and non-immunogenic. A further advantage is the ability of liposomes to 
isolate active substances during their passage through the organism, 
protecting them from enzymatic actions and also protecting the organism 
against toxic effects. 
 Liposomic formulations have demonstrated the ability to increase the 
penetration of drugs through the skin in comparison to conventional 
formulations. In addition, in open injuries, liposomes show the ability to 
accelerate healing [19]. 
 Various studies have shown promising results when investigating 
liposomal formulations containing sulphate of paramomycin (PM). In one 
study liposomal formulations of PM were assessed as topical delivery 
systems. Two types of liposomes were used: large multilamellar vesicles 
(MLVs) and large unilamellar vesicles (LUVs). Skin permeation experiments 
across stripped and normally hairless mouse skin were performed in modified 
Franz diffusion cells, revealing higher entrapment of paramomycin in LUV 
compared to MLV and better penetration into the skin with paromomycin 
liposomal encapsulation. The study concluded that liposomal formulations of 
paramomycin are an interesting alternative for the treatment of cutaneous 
leishmaniasis as they increase the skin penetration of paramomycin [20]. 
 In another study, liposomal formulations containing 10% and 15% 
paramomycin sulphate were developed to evaluate the antileishmanial 
activity of paramomycin against L. major-infected BALB/c mice. The study 
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also evaluated the penetration properties of PM into the skin, as this antibiotic 
shows a low level of penetration. Such low penetration reduces the 
effectiveness of paramomycin treatment of some injuries, particularly those 
that are not ulcerated, and is therefore a major drawback. The overall results 
of the study showed that liposomes are interesting paramomycin carriers and 
that liposomal PM could be a suitable candidate for the treatment of 
cutaneous leishmaniasis [21]. 
 
4.3. Combined treatment 
 
 Combination therapy provides several advantages: it reduces the duration 
of treatment, increases compliance, and reduces the dose of each drug, which 
helps to reduce the cost and side effects of therapy, as well as reducing the 
risk of emergence of resistance. Various authors have investigated different 
combination therapies with favorable results. One study verified the 
effectiveness of a combination of paramomycin gel and oral miltefosine in 
BALB/c mice infected with L. major for the treatment of cutaneous 
leishmaniasis. Miltefosine was administered orally at 2 mg/kg/day for                
10 days while the 10% paramomycin gel was applied twice daily for 10 days. 
This combination was highly effective, significantly reducing the size of the 
lesion and the load of parasites in the skin, and leading to complete healing of 
ulcers, in comparison with oral miltefosine alone [22]. 
 Other drugs such as azithromycin and allopurinol have been studied in 
the search for new therapies for cutaneous leishmaniasis. One study 
compared the efficacy and tolerance of azithromycin plus allopurinol with 
intramuscular Glucantime
®
, and found similar results. One of the benefits of 
allopurinol and azithromycin is that they are less expensive than Glucantime
®
 
and more readily available in developing countries. Furthermore, they are 
administered orally and therefore can be considered an alternative option to 
Glucantime
®
 treatment in patients who do not tolerate the latter [23]. 
 Another study evaluated the efficacy of combination with pentoxifylline 
and Glucantime
®
. Pentoxifylline is an inhibitor of TNF-α that has been 
shown to enhance the beneficial effects of antimonial compounds. The results 
of this study indicated that Glucantime
®
 with pentoxifylline is more effective 
than Glucantime
®
 alone. However, more tests are needed with different 
populations of patients with CL to demonstrate the real efficacy of the 
combination of pentoxifylline and Glucantime
®
 and develop specific 
treatment guidelines [24]. 
 The results of a study that evaluated the effectiveness of a combination of 
oral ketoconazole with intralesional estibogluconat sodium for the treatment 
of localized cutaneous leishmaniasis were promising. Furthermore, this 
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combination is easier to use, less aggressive and free of side effects compared 
to treatment with intralesional pentavalent antimonial compounds [25]. 
 A compound called Imiquimod, an inhibitor of tumor necrosis factor 
TNF-alpha, is useful in patients with moderate to severe psoriasis and other 
skin diseases and is currently used for the treatment of cervical warts caused 
by human papillomavirus infection. In vitro, this drug has proven to be an 
immunomodulator that activates macrophages to release nitric oxide, thus 
killing intracellular Leishmania amastigotes. A study evaluating combination 
therapy with Imiquimod and meglumine antimoniate in patients with 
cutaneous leishmaniasis  who previously had not responded to treatment with 
meglumine antimoniate alone showed promising results, as all patients 
responded well to combination therapy [26]. 
 
5. Conclusions 
 
 Intralesional and systemic therapy with pentavalent antimonials has been 
the treatment of choice for cutaneous leishmaniasis to date. 
 The application of paramomycin ointments to localized lesions and those 
less than 5 cm in diameter was the first attempt at local therapy and indicated 
the potential benefit of this type of administration. 
 The search for new drugs with anti-Leishmania activity is important for 
new treatments for CL. Avoiding the administration of derivatives of parenteral 
antimony greatly increases patient compliance and reduces treatment costs. 
 Studies of formulations based on liposomes and hydrophilic gels 
containing paromomycin indicate the effectiveness of these formulations in 
the topical treatment of cutaneous leishmaniasis. 
 Combination treatment has the potential advantages of: shortening the 
duration of treatment, thereby increasing compliance; reducing the overall 
dose of medicines, thereby reducing their toxic effects and cost; and reducing 
the probability of selection of drug-resistant parasites, thereby prolonging the 
effective life of the available medicines. 
 Due to the importance of this parasitic disease and the low efficiency of 
the limited therapies available, the search for new therapeutic alternatives 
against leishmaniasis is very important for the future treatment of cutaneous 
leishmaniasis. 
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